ARGX Argenx

$ARGX perfecr example of what it means to ride the 10/20 off into the sunset. Breaking out of its counter trend.

argenx $ARGX fell 16% in one day on Oct 8. Its Q2 sales were up 60%. Cause: a Phase 3 Sjögren's study stopped for futility Close Fri: €727.60 Q2 sales: $1.52B P/E 32 | fwd 25 Q3 results: Thu Oct 22 One setback, or a dent in the growth story? NFA #EuropeanStocks

$ARGX 🤝 argenx entered a definitive agreement to acquire Unnatural Products, Inc. for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion.

$ARGX Vyvgart sales came in at 1.72 billion dollars in Q3, up 54% from 1.13 billion a year ago. Pretty much the whole company is still this one drug, and it keeps growing like this. Operating profit was 486 million dollars though, below the 565.8 million average estimate (I/B/E/S, via Reuters). Operating margin slipped to 28.2% on costs from the 2.2 billion dollar Forte Biosciences deal, which closed in August. Profit for the period still rose to 506 million dollars from 344 million. Full-year R&D and SG&A is now expected around 4.0 billion dollars, Forte costs included.

$ARGX Follow-up: argenx Q3 profit $506M, $7.80 diluted EPS, on VYVGART sales up 54%. 🏢 Amsterdam immunology firm selling VYVGART; its Oct 19 6-K said the ALKIVIA myositis Phase 3 met its primary endpoint 📈 Q3 product net sales $1,721M vs $1,127M a year ago and $1,516M in Q2 🏦 Cash $3.7B on Sept 30 after ~$2.1B paid for Forte; market value ~$55B at $890.05, 16:00 ET Oct 21 🧾 Other side: ~$150M Forte costs held operating profit at $486M vs $493M in Q2; 2026 R&D+SG&A now ~$4B 📅 Next: EMPASSION Phase 3 topline in MMN expected in December 2026 Source: argenx Q3 release + SEC 6-K, Oct 22; SEC 6-K, Oct 19